

1 **Evolution of an enzyme conformational ensemble guides design of an efficient**
2 **biocatalyst**

3

4 **Aron Broom,^{1,†} Rojo V. Rakotoharisoa,^{1,†} Michael C. Thompson,² Niayesh Zarifi,¹ Erin**
5 **Nguyen,¹ Nurzhan Mukhametzhhanov,¹ Lin Liu,² James S. Fraser² & Roberto A. Chica^{1,*}**

6

7 ¹ Department of Chemistry and Biomolecular Sciences, University of Ottawa, 10 Marie Curie,
8 K1N 6N5, Ottawa, Ontario, Canada

9 ² Department of Bioengineering and Therapeutic Science, University of California, San
10 Francisco, San Francisco, California 94158, United States

11

12 [†] These authors contributed equally to this work.

13 ^{*} To whom correspondence should be addressed:

14 Roberto A. Chica, Email: rchica@uottawa.ca

15

16 **Abstract**

17 The creation of artificial enzymes is a key objective of computational protein design. Although *de*
18 *novo* enzymes have been successfully designed, these exhibit low catalytic efficiencies, requiring
19 directed evolution to improve activity. Here, we used room-temperature X-ray crystallography to
20 study changes in the conformational ensemble during evolution of the designed Kemp eliminase
21 HG3 (k_{cat}/K_M 160 M⁻¹s⁻¹). We observed that catalytic residues were increasingly rigidified, the
22 active site became better pre-organized, and its entrance was widened. Based on these
23 observations, we engineered HG4, an efficient biocatalyst (k_{cat}/K_M 120,000 M⁻¹s⁻¹) containing
24 active-site mutations found during evolution but not distal ones. HG4 structures revealed that its
25 active site was pre-organized and rigidified for efficient catalysis. Our results show how directed
26 evolution circumvents challenges inherent to enzyme design by shifting conformational ensembles
27 to favor catalytically-productive sub-states, and suggest improvements to the design methodology
28 that incorporate ensemble modeling of crystallographic data.

29 **Introduction**

30 Enzymes are the most efficient catalysts known, accelerating chemical reactions by up to
31 26 orders of magnitude¹ while displaying unmatched selectivity. The ability to create, from
32 scratch, an efficient artificial enzyme for any desired chemical reaction (i.e., a *de novo* enzyme) is
33 a key objective of computational protein design. Progress towards this goal has been made over
34 the past few decades following the development of computational enzyme design algorithms.^{2,3}
35 These methods have been used to create *de novo* enzymes for a variety of model organic
36 transformations including the Kemp elimination,^{4,5} retro-aldol,^{6,7} Diels-Alder,⁸ ester hydrolysis,⁹
37 and Morita-Baylis-Hilman¹⁰ reactions. Although successful, catalytic activities of *de novo*
38 enzymes have been modest, with k_{cat}/K_M values being several orders of magnitude lower than those
39 of natural enzymes.^{11,12} In addition, structural analyses of designed enzymes have revealed
40 important deficiencies in the computational methodologies, resulting in inaccurate predictions of
41 catalytic and ligand-binding interactions,⁵ and thereby low success rates,^{4,6,8} emphasizing the need
42 for continued development of robust enzyme design algorithms.

43 To improve the catalytic activity of designed enzymes, researchers have used directed
44 evolution. This process has yielded artificial enzymes displaying catalytic efficiencies approaching
45 those of their natural counterparts, and provided valuable information about the structural
46 determinants of efficient catalysis.^{4,13-15} During evolution, active-site residues, including designed
47 catalytic amino acids, were often mutated, leading to enhanced catalysis via optimization of
48 catalytic contacts, ligand binding modes, and transition-state complementarity.¹³⁻¹⁵ Directed
49 evolution has also yielded beneficial mutations at positions remote from the active site. Distal
50 mutations have been shown to enhance catalysis by shifting the populations of conformational sub-
51 states that enzymes sample on their energy landscape towards those that are more catalytically

52 active.¹⁶⁻¹⁸ Therefore, a better understanding of enzyme conformational ensembles, including the
53 effect of mutations on the population of sub-states, could provide valuable insights to aid in the
54 development of robust computational enzyme design methodologies.

55 Here, we study changes in the conformational ensemble along the evolutionary trajectory
56 of the *de novo* Kemp eliminase HG3 ($k_{\text{cat}}/K_{\text{M}}$ 160 M⁻¹s⁻¹) using room-temperature X-ray
57 crystallography. We observe that during evolution, catalytic residues were increasingly rigidified
58 through improved packing, the active site became better pre-organized to favor productive binding
59 of the substrate, and the active-site entrance was widened to facilitate substrate entry and product
60 release. Based on these observations, we generated a variant that contains all mutations necessary
61 to establish these structural features, which are found at positions within or close to the active site.
62 This variant, HG4, is >700-fold more active than HG3, with a catalytic efficiency on par with that
63 of the average natural enzyme ($k_{\text{cat}}/K_{\text{M}}$ 120,000 M⁻¹s⁻¹). Crystallographic analysis of HG4 reveals
64 that mutations proximal to the active site are sufficient to alter the conformational ensemble for
65 enrichment of catalytically-competent sub-states. Lastly, we demonstrate that HG4 can be
66 successfully designed using a crystallographically-derived ensemble of backbone templates
67 approximating conformational flexibility, but not with the single template used to design HG3,
68 offering insights for improving enzyme design methodologies.

69

70 **Results**

71 *HG series of Kemp eliminases*

72 Perhaps the most successful example of the improvement of a *de novo* enzyme by directed
73 evolution has been the engineering of HG3.17,¹⁵ the most active Kemp eliminase reported to
74 date.¹¹ This artificial enzyme, which catalyzes the deprotonation of 5-nitrobenzisoxazole into the

75 corresponding *o*-cyanophenolate (Figure 1a), was evolved from the *in silico* design HG3⁵ over 17
76 rounds of mutagenesis and screening that also yielded the HG3.3b, HG3.7, and HG3.14
77 intermediates (Figure 1b, Supplementary Table 1). A total of 17 mutations were introduced into
78 HG3 during evolution to produce HG3.17, resulting in a >1000-fold increase in catalytic efficiency
79 (Table 1, Supplementary Figure 1). Of these mutations, 11 occurred at positions within or close to
80 the active site, including 8 at positions that were optimized during computational design of HG3
81 (Table 1). One of the key active-site mutations occurred at position 50, which was mutated twice
82 during evolution, first from lysine to histidine (HG3 to HG3.3b) and then from histidine to
83 glutamine (HG3.3b to HG3.7), resulting in a novel catalytic residue ideally positioned for
84 stabilizing negative charge buildup on the phenolic oxygen at the transition state (Figure 1a).
85 Comparison of the crystal structure of the earlier *in silico* design HG2 (Supplementary Figure 2)
86 with that of a double mutant of HG3.17, in which surface mutations N47E and D300N were
87 reverted to the corresponding amino acids found in HG3 to facilitate crystallization (HG3.17-
88 E47N/N300D, PDB ID: 4BS0),¹⁵ revealed that catalytic activity was also enhanced via optimized
89 alignment of the transition-state analogue (TSA) with the catalytic base Asp127 (Figure 1c), and
90 improved active-site complementarity to this ligand (Figure 1d). Given that subtle changes to the
91 conformational ensemble of an enzyme can lead to significant rate enhancements,¹⁶⁻¹⁸ it is possible
92 that mutations in HG3.17 also contributed to enhanced catalytic efficiency by altering the
93 conformational landscape to enrich catalytically-competent sub-states. However, the structures of
94 HG2 and HG3.17-E47N/N300D were solved in the presence of bound TSA and at cryogenic
95 temperatures, which could have shifted the conformational ensemble towards a single predominant
96 sub-state, thereby limiting our ability to evaluate changes to the conformational landscape during
97 directed evolution.

98

99 *Room-temperature crystal structures*

100 To evaluate changes to the HG3 conformational ensemble along its evolutionary trajectory,
101 we solved room-temperature (277 K) X-ray crystal structures of all HG-series Kemp eliminases,
102 both in the presence and absence of bound TSA. Room-temperature X-ray crystallography can
103 reveal conformational heterogeneity in protein structures that would not be visible at cryogenic
104 temperatures and thereby provide insights into the conformational ensemble that is sampled by a
105 protein in solution.¹⁹ All five enzymes yielded crystals under similar conditions (Supplementary
106 Table 2), and these diffracted at resolutions of 1.35–1.99 Å (Supplementary Table 3). All unit cells
107 corresponded to space group P₂12₁2₁ with two protein molecules in the asymmetric unit, except
108 that of HG3.17, whose asymmetric unit was half the volume of the others and contained only one
109 polypeptide chain although the space group was also P₂12₁2₁. This result is in contrast with the
110 deposited structure of HG3.17-E47N/N300D, which contains two molecules in a unit cell of
111 identical space group and similar dimensions to those of all other HG variants reported here.¹⁵ This
112 discrepancy between our structure of HG3.17 and the previously published structure of HG3.17-
113 E47N/N300D is likely caused by the presence of the Asn47 surface residue in all variants except
114 for HG3.17, since this amino acid is involved in crystal packing interactions.

115 All HG-series enzymes bound the TSA in the same catalytically productive pose (Figure
116 2a) as that observed in HG2 and HG3.17-E47N/N300D (Figure 1c–d). In this pose, the acidic N–
117 H bond of the TSA that mimics the cleavable C–H bond of the substrate is located within
118 hydrogen-bonding distance to the carboxylate oxygen of Asp127 (2.5–2.6 Å distance between
119 heavy atoms), while the basic nitrogen atom corresponding to the phenolic oxygen of the transition
120 state forms an H-bond with either a water molecule (HG3), the N_ε atom of His50 (HG3.3b), or the

121 side-chain amide nitrogen of Gln50 (HG3.7, HG3.14, HG3.17). In addition to being held in place
122 by these polar interactions, the TSA is sandwiched between the hydrophobic side chains of Trp44
123 and Met237 (Figure 2b), which are part of a binding pocket that also includes the side chains of
124 Ala21, Met/Cys84, Met172, Leu236, Thr265, and Phe/Met267, as well as the backbone of Gly83
125 and Pro45 (Supplementary Figure 3). Interestingly, the *cis* peptide bond formed between residues
126 83 and 84 that is present in the original *Thermoascus aurantiacus* xylanase 10A template used to
127 design HG3 (PDB ID: 1GOR²⁰) is maintained in all HG structures (Figure 2c), even though both
128 residues were mutated to obtain HG3 (H83G and T84M). In addition to adopting a *cis*
129 conformation, which is stabilized by hydrogen bonding to an ordered water molecule, this peptide
130 bond also adopts the *trans* conformation in the structures of TSA-bound HG3 and HG3.3b.
131 However, starting at HG3.7, the peptide bond is found exclusively in the *cis* conformation in the
132 TSA-bound structures because it is stabilized by an additional hydrogen bond with the Gln50 side-
133 chain carbonyl oxygen. This hydrogen bonding interaction helps to lock Gln50 in a conformation
134 that is properly oriented to stabilize negative charge buildup on the phenolic oxygen at the
135 transition state, likely accounting for the majority of the 12-fold catalytic efficiency enhancement
136 observed in HG3.7 relative to HG3.3b (Table 1).

137 From HG3.7 to HG3.17, no further changes in catalytic residues occurred during evolution.
138 Yet, the catalytic efficiency increased by approximately 6-fold (Table 1). To evaluate whether this
139 increase in activity was caused by changes to the conformational ensemble, we analyzed the B-
140 factors of catalytic residues, which can be interpreted as a measure of the average displacement of
141 an atom, or group of atoms, in the crystal. Since both conformational heterogeneity and crystalline
142 disorder can contribute to atomic B-factors, with the latter effect potentially varying between
143 different crystals, we calculated the Z-scores of the atomic B-factors and compared those across

144 our crystal structures of different HG variants. This Z-score analysis allowed us to evaluate the
145 variation of B-factors relative to the mean value within an individual crystal, and showed that
146 rigidity of the Asp127 side chain did not vary significantly during evolution (Figure 3a). By
147 contrast, the side chain of residue 50 became increasingly rigidified over the course of the
148 evolutionary trajectory. Increasing rigidity at position 50 is expected when this residue is mutated
149 from a lysine to a histidine (HG3 to HG3.3b), given the lower number of degrees of freedom in
150 the latter amino acid. This trend is also expected when histidine at position 50 is mutated to a
151 glutamine (HG3.3b to HG3.7) given the ability of glutamine but not histidine to hydrogen-bond
152 with the *cis* peptide formed by residues Gly83 and Cys84 (Figure 2c). However, rigidity continues
153 to increase at this position between HG3.7 and HG3.17, even though the side-chain rotamer of
154 Gln50 in the presence of bound TSA remains the same (Figure 2a). This result suggests that other
155 structural features contribute to the increased rigidity observed at this position.

156 To verify the underlying cause of the increased rigidity at position 50, we calculated the
157 average Z-score of atomic B-factors for each residue. We observed a trend whereby the loop
158 formed by residues 87–90, which is located directly on top of residue 50, becomes increasingly
159 rigidified during evolution (Figure 3b). Interestingly, two residues forming this loop (89 and 90)
160 were mutated multiple times over the course of the evolutionary trajectory (Table 1). These
161 mutations induce a conformational change in the loop that moves it closer to the active site, which
162 results in a pi-stacking interaction between the phenyl and carboxamide groups of Phe90 and
163 Gln50 that increases rigidity of the catalytic residue (Figure 2d, Supplementary Figure 4a).

164 A key determinant of efficient enzyme catalysis is active site pre-organization, which
165 enables enzymes to bind substrates in a geometry close to that of the transition state. To evaluate
166 changes in active site pre-organization during evolution, we compared the structures of HG-series

167 Kemp eliminases in the presence and absence of bound TSA. In all enzymes except for HG3.17,
168 the unbound state is never pre-organized for catalysis as both Trp44 and Met237 adopt
169 conformations that would prevent productive binding of the TSA (Figure 2e). In addition, the
170 His50 and Gln50 catalytic residues in HG3.3b and HG3.7, respectively, adopt a low-occupancy,
171 catalytically non-productive conformation in the unbound state that cannot interact favorably with
172 the TSA. Interestingly, the non-productive conformation of Gln50 in the HG3.7 unbound state
173 (26% occupancy) cannot stabilize the *cis* peptide bond formed by residues 83 and 84 via a
174 hydrogen bonding interaction, and accordingly, the *trans* peptide conformation is also observed in
175 this structure (25% occupancy) (Supplementary Figure 4b).

176 In contrast with all other HG variants, the unbound state of HG3.17 is correctly pre-
177 organized for catalysis in a large portion of the molecules in the crystal, with only Trp44 adopting
178 a non-productive conformation at 62% occupancy (Figure 2e). In this variant, Met237 adopts
179 exclusively the productive conformer in the unbound state, which is stabilized by packing
180 interactions with the neighboring Met267 side chain, a mutation that was introduced late in the
181 evolutionary trajectory (HG3.14 to HG3.17). Overall, three of the four residues that are key for
182 binding and stabilizing the TSA (Gln50, Asp127, Met237) adopt a catalytically productive
183 conformation in the HG3.17 unbound state, resulting in approximately 40% of the molecules in
184 the crystal being correctly pre-organized for efficient catalysis.

185 Enhanced complementarity to the transition state is another important feature of efficient
186 catalysis. Therefore, computational enzyme design algorithms aim to optimize packing of the
187 transition state. However, transition-state overpacking may reduce catalytic efficiency by creating
188 a high-energy barrier preventing substrate entry and product release. To evaluate whether active-
189 site accessibility changed during evolution, we calculated the active-site entrance bottleneck radius

190 on TSA-bound structures.²¹ We observed that during evolution, the active-site bottleneck formed
191 by the side chains of residues 50 and 267, became widened (Figure 2f), as did the mouth of the
192 substrate entry channel formed by residues Arg275 and Trp276, which were mutated to smaller
193 amino acids. This widening of the active site entrance could help to eliminate high-energy barriers
194 to substrate entry and product release that could have been caused by tighter packing of the TSA
195 in higher activity HG variants.

196

197 *HG4, an efficient artificial enzyme*

198 All of the structural features that enhance activity described above are caused primarily by
199 residues within or close to the active site, which suggests that mutagenesis far from the active site
200 may not be essential to create an efficient artificial enzyme. To test this hypothesis, we generated
201 a variant of HG3 that contains all HG3.17 mutations found within 7.5 Å of the TSA, with the
202 exception of N47E, which we omitted to favor the formation of a unit cell similar to that of HG3.
203 We also included the R275A and W276F mutations found to widen the active site entrance. This
204 yielded HG4, a variant of HG3 containing 8 mutations (Table 1, Supplementary Table 1). Kinetic
205 analysis of HG4 revealed that its catalytic efficiency is >700-fold higher than that of HG3 (Table
206 1, Supplementary Figure 1), and equivalent to that of the average natural enzyme ($\sim 10^5 \text{ M}^{-1}\text{s}^{-1}$).²²
207 Crystallographic analysis of HG4 (Supplementary Tables 2–3) showed that its structure is highly
208 similar to that of HG3.17 but with an active site that is better pre-organized (Figure 2–3,
209 Supplementary Figure 3–4). Interestingly, both HG4 and HG3.17 have catalytic efficiencies on the
210 order of $10^5 \text{ M}^{-1} \text{ s}^{-1}$ despite the fact that the former enzyme contains less than half of the latter's
211 mutations, demonstrating that distal mutations in HG3.17 contribute little to its catalytic efficiency.

212

213 *Computational design of HG4*

214 Given that all but one mutation (G82A) in HG4 are found at sites that were optimized
215 during design of HG2,⁵ we investigated whether the HG4 structure could be accurately predicted
216 using a computational protocol similar to the one that produced HG2 (Methods, Supplementary
217 Tables 4–6). To do so, we first performed a positive control calculation in which rotamers for the
218 HG4 sequence were optimized on the crystal structure backbone of TSA-bound HG4. This
219 calculation yielded an *in silico* model of HG4 with an energy score and a predicted rotameric
220 configuration in excellent agreement with the crystal structure (Figure 4a). This control
221 demonstrates that the combination of energy function, rotamer library, and search algorithm used
222 in this protocol is sufficiently accurate for recapitulating the structure of HG4, provided that the
223 correct template, binding pose, and catalytic dyad is allowed. By contrast, when we replaced the
224 HG4 backbone template with the *Thermoascus aurantiacus* xylanase 10A backbone used to design
225 HG2 (PDB ID: 1GOR),²⁰ we obtained a structural model that differs significantly from the HG4
226 crystal structure and that is destabilized by approximately 40 kcal/mol (Figure 4b). This result
227 demonstrates that the 1GOR backbone template is not well-suited to accommodate the HG4
228 sequence, as evidenced by differences between the 1GOR-derived model and the HG4 crystal
229 structure. Specifically, the backbone at position 83 is shifted by 1.1 Å in the HG4 crystal structure
230 relative to its position in the 1GOR template, causing the transition state to adopt an alternate
231 binding pose that minimizes steric clashes with Gly83, which is accompanied by repacking of
232 several residues around the transition state, including Gln50. Use of our HG3 crystal structures
233 with or without TSA as the design template causes similar, but less severe, structural and energetic
234 effects (Figure 4c,d). However, when we optimized rotamers for the HG4 sequence on ensembles
235 of backbone templates generated using molecular dynamics restrained by the HG3 diffraction data

236 (Methods), we were able to recapitulate the correct transition-state binding mode on several
237 individual ensemble members, with energies comparable to that of the HG4 crystal structure
238 (Figure 4e–f, Supplementary Figure 5). These results highlight the impact of small backbone
239 geometry variations on the computational predictions, and suggest that computational enzyme
240 design with a crystallographically-derived backbone ensemble could obviate the need for directed
241 evolution by allowing catalytically-competent sub-states to be sampled during the design
242 procedure.

243

244 **Discussion**

245 In this work, we followed changes to the conformational ensemble that occur during
246 evolution of an enzyme with *de novo* biocatalytic function. Unlike previous examples where the
247 active sites of *de novo* enzymes were completely remodeled during evolution,^{23,24} or where the
248 binding pose of the substrate or transition state analogue was significantly altered,^{13,17} we observed
249 only subtle changes to the active site geometry or TSA binding pose in the HG-series of Kemp
250 eliminases. By contrast, many of the structural changes that contribute to enhanced catalysis in the
251 HG series are dynamic in nature: the Gln50 catalytic residue became more rigid even though its
252 average structure did not vary substantially, and the active site became better pre-organized via
253 enrichment of catalytically-productive conformations of TSA-binding residues that were already
254 present in the unbound state. These observations illustrate how small changes to the active site
255 conformational ensemble can drive large changes in catalytic efficiency. Since these changes can
256 be subtle and difficult to predict computationally, directed evolution can help increase activity by
257 selecting for mutations that enrich catalytically-competent sub-states.^{17,18}

258 Despite the challenges inherent to enzyme design, which are highlighted by our
259 observations of the effects of mutations in the HG series of Kemp eliminases, our results suggest
260 that *de novo* enzymes with native-like catalytic efficiencies can be computationally-designed,
261 without the need to rely on subsequent improvement by laboratory directed evolution. Indeed, all
262 mutations found in HG4 relative to the wild-type *Thermoascus aurantiacus* xylanase 10A template
263 from which it is derived (PDB ID: 1GOR) are found at either first or second-shell residues, and
264 these sites were all optimized during the original design of HG2.⁵ Yet, Privett *et al.* designed the
265 lower activity enzyme HG2 instead of HG4. While Gln50 was not sampled as part of the catalytic
266 dyad during design of HG2, the combination of the Asp127/Gln50 dyad with the productive
267 transition-state binding pose would have scored poorly on the 1GOR template regardless.
268 However, our approach to computational enzyme design that utilized an experimentally-derived
269 ensemble of backbone templates yielded HG4 models with energies and binding modes
270 comparable to that of the HG4 crystal structure. These results suggest an iterative approach to
271 computational enzyme design that could circumvent the need for directed evolution by introducing
272 an additional round of design that utilizes a backbone ensemble generated from experimental
273 structural data obtained for an initial, low-activity enzyme. In the case of evolution, mutations are
274 not selected for in the context of a single backbone conformation but instead across an entire
275 conformational ensemble.¹⁸ Our ensemble design approach should therefore be more accurate than
276 traditional approaches relying on a single backbone template because it allows the accessible
277 conformational ensemble to be represented in the scoring of sequences. The incorporation of
278 experimental restraints in the generation of the ensemble ensures that the computational procedure
279 is applied to the true conformational ensemble that is sampled by the enzyme.

280 The results reported here provide additional support for the well-known fact that enzymes
281 are plastic molecules whose backbone conformation can change upon introduction of mutations
282 (as seen when comparing the 1GOR and HG-series crystal structures), and suggest improvements
283 to the enzyme design protocol that can account for this property. This could be achieved by
284 incorporating flexible backbone design algorithms during the repacking step,^{25,26} or by using pre-
285 generated ensembles of energetically-accessible backbone templates,^{27,28} as was done here. While
286 these methodological changes may improve the design of the enzyme transition state, it is likely
287 that the creation of *de novo* enzymes with native-like catalytic efficiencies for more complex
288 reactions will require a holistic approach where every possible state that the enzyme samples along
289 its reaction coordinate is included in the design calculation. This could be achieved by the
290 implementation of multistate approaches to computational protein design that allow the design of
291 protein energy landscapes,²⁹ rather than single structures. We expect that the structures reported
292 here, especially those of HG4 and HG3, will be helpful to benchmark these future enzyme design
293 protocols.

294

295 **Methods**

296 *Protein expression and purification.* Codon-optimized and his-tagged (C-terminus) genes for HG-
297 series Kemp eliminases (Supplementary Table 1) cloned into the pET-11a vector (Novagen) via
298 *Nde*I and *Bam*HI were obtained from Genscript. Enzymes were expressed in *E. coli* BL21-Gold
299 (DE3) cells (Agilent) using lysogeny broth (LB) supplemented with 100 µg/mL ampicillin.
300 Cultures were grown at 37 °C with shaking to an optical density at 600 nm of 0.3, at which point
301 the incubation temperature was reduced to 18 °C. At an OD600 of 0.6, protein expression was
302 initiated with 1 mM isopropyl β-D-1-thiogalactopyranoside. Following incubation for 16 hours at

303 18 °C with shaking (250 rpm), cells were harvested by centrifugation, resuspended in 10 mL lysis
304 buffer (5 mM imidazole in 100 mM potassium phosphate buffer, pH 8.0), and lysed with an
305 EmulsiFlex-B15 cell disruptor (Avestin). Proteins were purified by immobilized metal affinity
306 chromatography according to the manufacturer's protocol (Qiagen), followed by gel filtration in
307 50 mM sodium citrate buffer (pH 5.5) and 150 mM sodium chloride using an ENrich SEC 650
308 size-exclusion chromatography column (Bio-Rad). Purified samples were concentrated using
309 Amicon Ultracel-10K centrifugal filter units (EMD Millipore).

310

311 *Steady-state kinetics.* All assays were carried out at 27 °C in 100 mM sodium phosphate buffer
312 (pH 7.0) supplemented with 100 mM sodium chloride. Triplicate reactions with varying
313 concentrations of 5-nitrobenzisoxazole (AstaTech) dissolved in methanol (10% final
314 concentration) were initiated by addition of approximately 2 µM HG3, 50 nM HG3.3b, 10 nM
315 HG3.7/HG3.14, or 5 nM HG3.17/HG4. Product formation was monitored spectrophotometrically
316 at 380 nm ($\epsilon = 15,800 \text{ M}^{-1} \text{ cm}^{-1}$).⁵ Linear phases of the kinetic traces were used to measure initial
317 reaction rates. Initial reaction rates at different substrate concentrations were fit to the Michaelis-
318 Menten equation using GraphPad Prism.

319

320 *Crystallization.* Enzyme variants were prepared in 50 mM sodium citrate buffer (pH 5.5) at the
321 concentrations listed in Supplementary Table 2. For samples that were co-crystallized with the
322 transition state analog (TSA) 5-nitrobenzotriazole (AstaTech), a 100 mM stock solution of the
323 TSA was prepared in dimethylsulfoxide (DMSO) and diluted 20-fold in the enzyme solutions for
324 a final concentration of 5 mM TSA (5% DMSO). For each enzyme variant, we carried out initial
325 crystallization trials in 15-well hanging drop format using EasyXtal crystallization plates (Qiagen)

326 and a crystallization screen that was designed to explore the chemical space around the
327 crystallization conditions reported by Blomberg *et al.*¹⁵ Crystallization drops were prepared by
328 mixing 1 μ L of protein solution with 1 μ L of the mother liquor, and sealing the drop inside a
329 reservoir containing an additional 500 μ L of the mother liquor solution. The mother liquor
330 solutions contained ammonium sulfate as a precipitant in sodium acetate buffer (100 mM), and the
331 specific growth conditions that yielded the crystals used for X-ray data collection are provided in
332 Supplementary Table 2. In some cases, a microseeding protocol was required to obtain high-
333 quality crystals. Microseeds were prepared by vortexing crystals in their mother liquor in the
334 presence of glass beads (0.5 mm), and were subsequently diluted into the mother liquor solutions
335 used to form the crystallization drops.

336

337 *X-ray data collection and processing.* Prior to X-ray data collection, crystals were mounted in
338 polyimide loops and sealed using a MicroRT tubing kit (MiTeGen). Single-crystal X-ray
339 diffraction data was collected on beamline 8.3.1 at the Advanced Light Source. The beamline was
340 equipped with a Pilatus3 S 6M detector, and was operated at a photon energy of 11111 eV. Crystals
341 were maintained at 277 K throughout the course of data collection. Each data set was collected
342 using a total X-ray dose of 200 kGy or less, and covered a 180° wedge of reciprocal space. Multiple
343 data sets were collected for each enzyme variant.

344 X-ray data was processed with the Xia2 program
345 (<https://doi.org/10.1107/S0021889809045701>), which performed indexing, integration, and
346 scaling with XDS and XSCALE³⁰ followed by merging with Pointless.³¹ For each variant,
347 multiple individual data sets were merged to obtain the final set of reduced intensities, and the
348 resolution cutoff was taken where the CC_{1/2} and $\langle I/\sigma I \rangle$ values for the merged intensities fell to

349 approximately 0.5 and 1.0 respectively. Information regarding data collection and processing is
350 presented in Supplementary Table 3. The reduced diffraction data were analyzed with
351 phenix.xtriage (http://www ccp4.ac.uk/newsletters/newsletter43/articles/PHZ_RWGK_PDA.pdf)
352 to check for crystal pathologies, and no complications were identified.

353
354 *Structure determination.* We obtained initial phase information for calculation of electron density
355 maps by molecular replacement using the program Phaser,³² as implemented in the PHENIX
356 suite.³³ Several different HG-series enzymes were used as molecular replacement search models.
357 All members of the HG-series of enzymes crystallized in the same crystal form, containing two
358 copies of the molecule in the crystallographic asymmetric unit, except for HG3.17, which
359 crystallized with only one molecule in the asymmetric unit. To avoid model bias that could
360 originate from using other members of the HG-series as molecular replacement search models, we
361 applied random coordinate displacements ($\sigma = 0.5 \text{ \AA}$) to the atoms, and performed coordinate
362 refinement against the structure factor data before proceeding to manual model building.

363 Next, we performed iterative steps of manual model rebuilding followed by refinement of
364 atomic positions, atomic displacement parameters, and occupancies using a translation-libration-
365 screw (TLS) model, a riding hydrogen model, and automatic weight optimization. All model
366 building was performed using Coot³⁴ and refinement steps were performed with phenix.refine
367 (v1.13-2998) within the PHENIX suite.^{33,35} Restraints for the TSA were generated using
368 phenix.elbow,³⁶ starting from coordinates available in the Protein Data Bank (PDB ligand ID:
369 6NT).³⁷ Further information regarding model building and refinement, as well as PDB accession
370 codes for the final models, are presented in Supplementary Table 3. Time-averaged ensembles
371 were generated for HG3 with and without ligand with phenix.ensemble_refinement implemented

372 in PHENIX. To prepare the structures for ensemble refinement, low-occupancy conformers were
373 removed, and occupancies adjusted to 100% using phenix.pdbtools. Hydrogen atoms were then
374 added using phenix.ready_set. This procedure yielded 79- and 49-member ensembles from the
375 HG3 structures with and without TSA, respectively.

376

377 *Computational enzyme design.* All calculations were performed with the Triad protein design
378 software (Protabit, Pasadena, CA, USA) using a Monte Carlo with simulated annealing search
379 algorithm for rotamer optimization. The crystal structure of *Thermoascus aurantiacus* xylanase
380 10A was obtained from the Protein Data Bank (PDB code: 1GOR²⁰) and further refined as
381 described above to fix modeling issues with Thr84. Structures of HG3 with and without TSA, HG4
382 with TSA, and ensembles of HG3-derived templates were obtained from refinement of
383 crystallographic data as described above. Following extraction of protein heavy-atom coordinates
384 for the highest occupancy conformer from chain A, hydrogen atoms were added using the *addH.py*
385 application in Triad. The Kemp elimination transition state (TS) structure³⁸ was built using the
386 parameters described by Privett and coworkers.⁵ Residue positions surrounding Asp127 were
387 mutated to Gly (Supplementary Table 4), with the exception of position 50, which was mutated to
388 Gln. A backbone-independent rotamer library³⁹ with expansions of ± 1 standard deviation around
389 χ_1 and χ_2 was used to provide side-chain conformations. A library of TS poses was generated in
390 the active site by targeted ligand placement² using the contact geometries listed in Supplementary
391 Table 5. TS pose energies were calculated using the PHOENIX energy function,⁵ which consists
392 of a Lennard-Jones 12–6 van der Waals term from the Dreiding II force field⁴⁰ with atomic radii
393 scaled by 0.9, a direction-dependent hydrogen bond term with a well depth of 8.0 kcal mol⁻¹ and
394 an equilibrium donor-acceptor distance of 2.8 Å,⁴¹ an electrostatic energy term modelled using

395 Coulomb's law with a distance-dependent dielectric of 10, an occlusion-based solvation potential
396 with scale factors of 0.05 for nonpolar burial, 2.5 for nonpolar exposure, and 1.0 for polar burial,⁴²
397 and a secondary structural propensity term.⁴³ During the energy calculation step, TS–side-chain
398 interaction energies were biased to favor interactions that satisfy contact geometries
399 (Supplementary Table 6) as described by Lassila *et al.*²

400 Following ligand placement, the 10 lowest energy TS poses found on each template (HG4
401 with TSA, 1GOR, HG3 with TSA, and HG3 without TSA) were selected as starting points for
402 repacking of the HG4 sequence. For individual members of the crystallographically-derived
403 ensembles, only the single lowest energy TS pose was used for repacking. In the repacking
404 calculation, the TS structure was translated ± 0.4 Å in each Cartesian coordinate in 0.2-Å steps,
405 and rotated 10° about all three axes (origin at TS geometric center) in 5° steps for a total
406 combinatorial rotation/translation search size of 5⁶ or 15,625 poses. Residues that were converted
407 to Gly in the ligand placement step were allowed to sample all conformations of the amino acid
408 found at that position in the HG4 sequence (Supplementary Table 4). The identities of the catalytic
409 residues were fixed and allowed to sample all conformations of that amino-acid type. Side-chain–
410 TS interaction energies were biased to favor those contacts that satisfy the geometries as done
411 during the ligand placement step (Supplementary Table 6). Rotamer optimization was carried out
412 using the search algorithm, rotamer library, and energy function described above. The single
413 lowest energy repacked structure on each backbone template was used for analysis. To compare
414 energies of the HG4 models obtained on the various templates, we calculated the energy difference
415 between each repacked structure and the corresponding all-Gly structure obtained after ligand
416 placement, and these energies are reported throughout the figures and text.

417

418 *Statistics and reproducibility.* Experiments were repeated in triplicate where feasible. All
419 replications were successful and the resulting data is presented with error values representing the
420 standard deviation between replicates. No data was excluded from analyses.

421

422 **Data availability**

423 Structure coordinates for all HG-series Kemp eliminases have been deposited in the Protein Data
424 Bank with the following accession codes: HG3 (PDB ID: 5RG4, 5RGA), HG3.3b (PDB ID: 5RG5,
425 5RGB), HG3.7 (PDB ID: 5RG6, 5RGC), HG3.14 (PDB ID: 5RG7, 5RGD), HG3.17 (PDB ID:
426 5RG8, 5RGE), and HG4 (PDB ID: 5RG9, 5RGF).

427

428 **Acknowledgments**

429 R.A.C. acknowledges an Early Researcher Award from the Ontario Ministry of Economic
430 Development & Innovation (ER14-10-139), and grants from the Natural Sciences and Engineering
431 Research Council of Canada (NSERC, RGPIN-2016-04831) and the Canada Foundation for
432 Innovation (26503). J.S.F. is supported by a Searle Scholar Award from the Kinship Foundation,
433 a Pew Scholar Award from the Pew Charitable Trusts, a Packard Fellowship from the David and
434 Lucile Packard Foundation, NIH GM110580, UC Office of the President Laboratory Fees
435 Research Program LFR-17-476732, and NSF STC-1231306. A.B. is the recipient of a postdoctoral
436 fellowship from NSERC. M.C.T. is supported by a Ruth L. Kirschstein National Research Service
437 Award (F32 HL129989). We thank Dr. Heidi K. Privett for providing HG2 design scripts and
438 computational model, and Dr. Justin T. Biel for assistance with initial processing of X-ray datasets.

439

440 Data collection at Beamline 8.3.1 at the Advanced Light Sources is supported by the University of
441 California Office of the President, Multicampus Research Programs and Initiatives grant MR-15-
442 328599, the Program Breakthrough Biomedical Research (which is partially funded by the Sandler
443 Foundation), the National Institutes of Health (R01 GM124149 and P30 GM124169), Plexxikon
444 Inc., and the Integrated Diffraction Analysis Technologies program of the US Department of
445 Energy Office of Biological and Environmental Research. The Advanced Light Source (Berkeley,
446 CA) is a national user facility operated by Lawrence Berkeley National Laboratory on behalf of
447 the US Department of Energy under contract number DE-AC02-05CH11231, Office of Basic
448 Energy Sciences.

449

450 **Author Contributions**

451 A.B. and R.A.C. conceived the project. A.B., N.Z., E.N., N.M., and L.L. purified proteins. A.B.
452 and N.Z. performed enzyme kinetics experiments. R.A.C. and M.C.T. crystallized proteins and
453 performed X-ray diffraction experiments. A.B., R.V.R., M.C.T., and R.A.C. performed
454 refinements. M.C.T. and J.S.F. designed X-ray crystallography experiments. A.B. and R.V.R.
455 performed computational design experiments. R.A.C. wrote the manuscript. A.B., R.V.R., and
456 M.C.T. edited the manuscript.

457

458 **Competing Interests**

459 The authors declare no competing interests.

460 **References**

461 (1) Edwards, D. R.; Lohman, D. C.; Wolfenden, R. Catalytic proficiency: the extreme case of
462 S-O cleaving sulfatases *J Am Chem Soc* **134**,525-531 (2012).

463 (2) Lassila, J. K.; Privett, H. K.; Allen, B. D.; Mayo, S. L. Combinatorial methods for small-
464 molecule placement in computational enzyme design *Proc Natl Acad Sci U S A* **103**,16710-16715 (2006).

465 (3) Zanghellini, A.; Jiang, L.; Wollacott, A. M.; Cheng, G.; Meiler, J.; Althoff, E. A.;
466 Rothlisberger, D.; Baker, D. New algorithms and an in silico benchmark for computational enzyme design
467 *Protein Sci* **15**,2785-2794 (2006).

468 (4) Rothlisberger, D.; Khersonsky, O.; Wollacott, A. M.; Jiang, L.; DeChancie, J.; Betker, J.;
469 Gallaher, J. L.; Althoff, E. A.; Zanghellini, A.; Dym, O.; Albeck, S.; Houk, K. N.; Tawfik, D. S.; Baker, D. Kemp
470 elimination catalysts by computational enzyme design *Nature* **453**,190-195 (2008).

471 (5) Privett, H. K.; Kiss, G.; Lee, T. M.; Blomberg, R.; Chica, R. A.; Thomas, L. M.; Hilvert, D.;
472 Houk, K. N.; Mayo, S. L. Iterative approach to computational enzyme design *Proc Natl Acad Sci U S A*
473 **109**,3790-3795 (2012).

474 (6) Jiang, L.; Althoff, E. A.; Clemente, F. R.; Doyle, L.; Röthlisberger, D.; Zanghellini, A.;
475 Gallaher, J. L.; Betker, J. L.; Tanaka, F.; Barbas, C. F., 3rd; Hilvert, D.; Houk, K. N.; Stoddard, B. L.; Baker, D.
476 De novo computational design of retro-aldol enzymes *Science* **319**,1387-1391 (2008).

477 (7) Althoff, E. A.; Wang, L.; Jiang, L.; Giger, L.; Lassila, J. K.; Wang, Z.; Smith, M.; Hari, S.;
478 Kast, P.; Herschlag, D.; Hilvert, D.; Baker, D. Robust design and optimization of retroaldol enzymes
479 *Protein Sci* **21**,717-726 (2012).

480 (8) Siegel, J. B.; Zanghellini, A.; Lovick, H. M.; Kiss, G.; Lambert, A. R.; St Clair, J. L.; Gallaher,
481 J. L.; Hilvert, D.; Gelb, M. H.; Stoddard, B. L.; Houk, K. N.; Michael, F. E.; Baker, D. Computational design
482 of an enzyme catalyst for a stereoselective bimolecular Diels-Alder reaction *Science* **329**,309-313 (2010).

483 (9) Richter, F.; Blomberg, R.; Khare, S. D.; Kiss, G.; Kuzin, A. P.; Smith, A. J.; Gallaher, J.;
484 Pianowski, Z.; Helgeson, R. C.; Grjasnow, A.; Xiao, R.; Seetharaman, J.; Su, M.; Vorobiev, S.; Lew, S.;
485 Forouhar, F.; Kornhaber, G. J.; Hunt, J. F.; Montelione, G. T.; Tong, L.; Houk, K. N.; Hilvert, D.; Baker, D.
486 Computational design of catalytic dyads and oxyanion holes for ester hydrolysis *J Am Chem Soc*
487 **134**,16197-16206 (2012).

488 (10) Bjelic, S.; Nivón, L. G.; Çelebi-Ölçüm, N.; Kiss, G.; Rosewall, C. F.; Lovick, H. M.; Ingalls, E.
489 L.; Gallaher, J. L.; Seetharaman, J.; Lew, S.; Montelione, G. T.; Hunt, J. F.; Michael, F. E.; Houk, K. N.;
490 Baker, D. Computational design of enone-binding proteins with catalytic activity for the Morita-Baylis-
491 Hillman reaction *ACS Chem Biol* **8**,749-757 (2013).

492 (11) St-Jacques, A. D.; Gagnon, O.; Chica, R. A. In *Modern Biocatalysis: Advances Towards
493 Synthetic Biological Systems*; The Royal Society of Chemistry: 2018, p 88-116.

494 (12) Mak, W. S.; Siegel, J. B. Computational enzyme design: transitioning from catalytic
495 proteins to enzymes *Curr Opin Struct Biol* **27**,87-94 (2014).

496 (13) Khersonsky, O.; Kiss, G.; Rothlisberger, D.; Dym, O.; Albeck, S.; Houk, K. N.; Baker, D.;
497 Tawfik, D. S. Bridging the gaps in design methodologies by evolutionary optimization of the stability and
498 proficiency of designed Kemp eliminase KE59 *Proc Natl Acad Sci U S A* **109**,10358-10363 (2012).

499 (14) Khersonsky, O.; Rothlisberger, D.; Wollacott, A. M.; Murphy, P.; Dym, O.; Albeck, S.; Kiss,
500 G.; Houk, K. N.; Baker, D.; Tawfik, D. S. Optimization of the in-silico-designed kemp eliminase KE70 by
501 computational design and directed evolution *J Mol Biol* **407**,391-412 (2011).

502 (15) Blomberg, R.; Kries, H.; Pinkas, D. M.; Mittl, P. R.; Grutter, M. G.; Privett, H. K.; Mayo, S.
503 L.; Hilvert, D. Precision is essential for efficient catalysis in an evolved Kemp eliminase *Nature* **503**,418-
504 421 (2013).

505 (16) Romero-Rivera, A.; Garcia-Borras, M.; Osuna, S. Role of Conformational Dynamics in the
506 Evolution of Retro-Aldolase Activity *Acs Catalysis* **7**,8524-8532 (2017).

507 (17) Hong, N. S.; Petrovic, D.; Lee, R.; Gryn'ova, G.; Purg, M.; Saunders, J.; Bauer, P.; Carr, P.
508 D.; Lin, C. Y.; Mabbitt, P. D.; Zhang, W.; Altamore, T.; Easton, C.; Coote, M. L.; Kamerlin, S. C. L.; Jackson,
509 C. J. The evolution of multiple active site configurations in a designed enzyme *Nat Commun* **9**,3900
510 (2018).

511 (18) Campbell, E.; Kaltenbach, M.; Correy, G. J.; Carr, P. D.; Porebski, B. T.; Livingstone, E. K.;
512 Afriat-Jurnou, L.; Buckle, A. M.; Weik, M.; Hollfelder, F.; Tokuriki, N.; Jackson, C. J. The role of protein
513 dynamics in the evolution of new enzyme function *Nat Chem Biol* **12**,944-950 (2016).

514 (19) Biel, J. T.; Thompson, M. C.; Cunningham, C. N.; Corn, J. E.; Fraser, J. S. Flexibility and
515 Design: Conformational Heterogeneity along the Evolutionary Trajectory of a Redesigned Ubiquitin
516 *Structure* **25**,739-749 e733 (2017).

517 (20) Lo Leggio, L.; Kalogiannis, S.; Eckert, K.; Teixeira, S. C.; Bhat, M. K.; Andrei, C.; Pickersgill,
518 R. W.; Larsen, S. Substrate specificity and subsite mobility in *T. aurantiacus* xylanase 10A *FEBS Lett*
519 **509**,303-308 (2001).

520 (21) Chovancova, E.; Pavelka, A.; Benes, P.; Strnad, O.; Brezovsky, J.; Kozlikova, B.; Gora, A.;
521 Sustr, V.; Klvana, M.; Medek, P.; Biedermannova, L.; Sochor, J.; Damborsky, J. CAVER 3.0: a tool for the
522 analysis of transport pathways in dynamic protein structures *PLoS Comput Biol* **8**,e1002708 (2012).

523 (22) Bar-Even, A.; Noor, E.; Savir, Y.; Liebermeister, W.; Davidi, D.; Tawfik, D. S.; Milo, R. The
524 moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme parameters
525 *Biochemistry* **50**,4402-4410 (2011).

526 (23) Giger, L.; Caner, S.; Obexer, R.; Kast, P.; Baker, D.; Ban, N.; Hilvert, D. Evolution of a
527 designed retro-aldolase leads to complete active site remodeling *Nat Chem Biol* **9**,494-498 (2013).

528 (24) Obexer, R.; Godina, A.; Garrabou, X.; Mittl, P. R.; Baker, D.; Griffiths, A. D.; Hilvert, D.
529 Emergence of a catalytic tetrad during evolution of a highly active artificial aldolase *Nat Chem* **9**,50-56
530 (2017).

531 (25) Friedland, G. D.; Linares, A. J.; Smith, C. A.; Kortemme, T. A simple model of backbone
532 flexibility improves modeling of side-chain conformational variability *J Mol Biol* **380**,757-774 (2008).

533 (26) Babor, M.; Mandell, D. J.; Kortemme, T. Assessment of flexible backbone protein design
534 methods for sequence library prediction in the therapeutic antibody Herceptin-HER2 interface *Protein*
535 *Sci* **20**,1082-1089 (2011).

536 (27) Davey, J. A.; Chica, R. A. Improving the accuracy of protein stability predictions with
537 multistate design using a variety of backbone ensembles *Proteins* **82**,771-784 (2014).

538 (28) Davey, J. A.; Chica, R. A. Multistate Computational Protein Design with Backbone
539 Ensembles *Methods Mol Biol* **1529**,161-179 (2017).

540 (29) Davey, J. A.; Damry, A. M.; Goto, N. K.; Chica, R. A. Rational design of proteins that
541 exchange on functional timescales *Nat Chem Biol* **13**,1280-1285 (2017).

542 (30) Kabsch, W. Xds *Acta Crystallogr D Biol Crystallogr* **66**,125-132 (2010).

543 (31) Evans, P. Scaling and assessment of data quality *Acta Crystallogr D Biol Crystallogr*
544 **62**,72-82 (2006).

545 (32) McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R.
546 J. Phaser crystallographic software *J Appl Crystallogr* **40**,658-674 (2007).

547 (33) Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J.
548 J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R.
549 J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive Python-
550 based system for macromolecular structure solution *Acta Crystallogr D Biol Crystallogr* **66**,213-221
551 (2010).

552 (34) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot
553 *Acta Crystallogr D Biol Crystallogr* **66**,486-501 (2010).

554 (35) Afonine, P. V.; Grosse-Kunstleve, R. W.; Echols, N.; Headd, J. J.; Moriarty, N. W.;
555 Mustyakimov, M.; Terwilliger, T. C.; Urzhumtsev, A.; Zwart, P. H.; Adams, P. D. Towards automated
556 crystallographic structure refinement with phenix.refine *Acta Crystallogr D Biol Crystallogr* **68**,352-367
557 (2012).

558 (36) Moriarty, N. W.; Grosse-Kunstleve, R. W.; Adams, P. D. electronic Ligand Builder and
559 Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation *Acta Crystallogr*
560 *D Biol Crystallogr* **65**,1074-1080 (2009).

561 (37) Bernstein, F. C.; Koetzle, T. F.; Williams, G. J.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.;
562 Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: a computer-based archival file for
563 macromolecular structures *J Mol Biol* **112**,535-542 (1977).

564 (38) Na, J.; Houk, K. N.; Hilvert, D. Transition state of the base-promoted ring-opening of
565 isoxazoles. Theoretical prediction of catalytic functionalities and design of haptens for antibody
566 production *Journal of the American Chemical Society* **118**,6462-6471 (1996).

567 (39) Dunbrack, R. L.; Cohen, F. E. Bayesian statistical analysis of protein side-chain rotamer
568 preferences *Protein Science* **6**,1661-1681 (1997).

569 (40) Mayo, S. L.; Olafson, B. D.; Goddard, W. A. Dreiding - a Generic Force-Field for Molecular
570 Simulations *Journal of Physical Chemistry* **94**,8897-8909 (1990).

571 (41) Dahiyat, B. I.; Mayo, S. L. Probing the role of packing specificity in protein design *Proc
572 Natl Acad Sci U S A* **94**,10172-10177 (1997).

573 (42) Chica, R. A.; Moore, M. M.; Allen, B. D.; Mayo, S. L. Generation of longer emission
574 wavelength red fluorescent proteins using computationally designed libraries *Proc Natl Acad Sci U S A*
575 **107**,20257-20262 (2010).

576 (43) Shortle, D. Propensities, Probabilities, and the Boltzmann Hypothesis *Protein Sci*
577 **12**,1298-1302 (2003).

578 (44) Morozov, A. V.; Kortemme, T.; Tsemekhman, K.; Baker, D. Close agreement between the
579 orientation dependence of hydrogen bonds observed in protein structures and quantum mechanical
580 calculations *Proc Natl Acad Sci U S A* **101**,6946-6951 (2004).

581

582 **Table 1. Kinetic parameters of Kemp eliminases**

583

Enzyme	Mutations from HG3 ^a	k_{cat} / K_M (M ⁻¹ s ⁻¹) ^b
HG3	-	160 ± 10 (1300)
HG3.3b	V6I <i>K50H M84C S89R Q90D A125N</i>	2300 ± 800 (5400)
HG3.7	V6I Q37K <i>K50Q M84C S89R Q90H A125N</i>	28000 ± 4000 (37000)
HG3.14	V6I Q37K <i>K50Q G82A M84C Q90H T105I A125T T142N T208M T279S D300N</i>	55000 ± 4000 (70000)
HG3.17	V6I Q37K <i>N47E K50Q G82A M84C S89N Q90F T105I A125T T142N T208M F267M W275A R276F T279S D300N</i>	170000 ± 20000 (230000)
HG4	<i>K50Q G82A M84C Q90F A125T F267M W275A R276F</i>	120000 ± 10000

584


585 ^aMutations in italics occurred at sites optimized during computational design of HG3.⁵

586 ^bIndividual parameters K_M and k_{cat} could not be determined accurately because saturation was not possible at the
587 maximum substrate concentration tested (2 mM). Experiments were performed in triplicate using enzymes from at
588 least two independent enzyme preparations (mean ± s.d.). Values in parentheses are from Blomberg *et al.*¹⁵

589

590 **Figures**

591



592

593 **Figure 1. HG series of Kemp eliminases.** (a) HG enzymes catalyze the Kemp elimination reaction using a catalytic
594 dyad consisting of a base (Asp127) that deprotonates 5-nitrobenzisoxazole, and an H-bond donor (Gln50) that
595 stabilizes negative charge buildup on the phenolic oxygen at the transition state (\ddagger). This reaction yields 4-nitro-2-
596 cyanophenol. (b) Directed evolution of the *in silico* design HG3, which itself is a single mutant (S265T) of the earlier
597 design HG2. A total of 17 mutations (shown as spheres) were introduced during evolution, including 11 at positions
598 within or close to the active site (green) and 6 at distal sites (magenta). (c) Angles describing the hydrogen bonding
599 interaction between the transition state analog (TSA) and Asp127 in the HG2 (PDB ID: 3NYD)⁵ and HG3.17-
600 E47N/N300D (PDB ID: 4BS0)¹⁵ crystal structures are indicated in grey and black, respectively. Values in italics are
601 optimal angles calculated for hydrogen bonding interactions between acetamide dimers.⁴⁴ (d) Cut-away view of the
602 active site pocket shows that its structural complementarity with the TSA (spheres) is improved in the higher activity
603 variant HG3.17-E47N/N300D. Key active site residues are shown as sticks.
604





Figure 2. Crystal structures of HG-series Kemp eliminases. In all cases, only atoms from chain A are shown. (a) Binding pose of the transition state analogue (TSA, orange). Hydrogen bonds are shown as dashed lines. The red sphere represents a water molecule. The 2Fo-Fc map is shown in volume representation at two contour levels: $0.5 \text{ e}\text{\AA}^{-3}$ and $1.5 \text{ e}\text{\AA}^{-3}$ in light and dark blue, respectively. (b) The TSA (orange) is sandwiched between the hydrophobic side chains of Trp44 and Met237. (c) The peptide bond between residues 83 and 84 can adopt *cis* or *trans* conformations. Hydrogen bonds are shown as dashed lines. The 2Fo-Fc map is shown in volume representation at two contour levels: $0.5 \text{ e}\text{\AA}^{-3}$ and $1.5 \text{ e}\text{\AA}^{-3}$ in light and dark blue, respectively. (d) Conformational changes to loop formed by residues 87–90 over the course of the evolutionary trajectory. The 2Fo-Fc map is shown in volume representation at two contour levels: $0.50 \text{ e}\text{\AA}^{-3}$ and $1.5 \text{ e}\text{\AA}^{-3}$ in light and dark blue, respectively. (e) Superposition of the TSA-bound structure (white) with the highest (magenta) and lowest (green) occupancy conformers of the unbound structure for each Kemp eliminase. The occupancies of non-productive conformers of Trp44 in the unbound structures of HG3.17 and HG4 are 62% and 26%, respectively. (f) Cut-away view of the active site shows that its entrance (top) becomes widened during evolution, as indicated by an increasing bottleneck radius (reported as the average radius \pm s.d. calculated using the highest occupancy conformers from both chain A and B, except for HG3.17, which contains a single chain). The TSA is shown as orange spheres. Bottleneck radii were calculated using the PyMOL plugin Caver 3.0.²¹

605
606

607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622



623


624

625

Figure 3. Conformational heterogeneity. (a) B-factor Z-scores for the residue at position 50 in the absence of bound TSA decrease over the course of the evolutionary trajectory, while those for Asp127 do not change significantly. Z-scores of individual side-chain atoms are shown as dots, while the average is indicated by the bar. Positive and negative Z-scores indicate increased flexibility or rigidity relative to the average residue in the protein, respectively. (b) B-factor Z-scores for all protein residues in the absence of bound TSA plotted on a model backbone for each Kemp eliminase. Thickness of the sausage plot increases with the B-factor Z-score, indicating increased flexibility. The loop formed by residues 87–90 (boxed) becomes more rigid during evolution.

631

632



633
634
635 **Figure 4. Computational design of HG4 on various backbone templates.** The HG4 crystal structure with bound
636 TSA (white) is overlaid on the HG4 design models (colored) obtained using the crystal structure of (a) HG4 with
637 bound TSA, (b) *Thermoascus aurantiacus* xylanase 10A (PDB ID: 1GOR), (c) HG3 with bound TSA, or
638 (d) HG3 without TSA. Panels (e) and (f) show the HG4 design models obtained using the template prepared by
639 ensemble refinement from the corresponding HG3 density map that gave the best energy following repacking.
640 PHOENIX energies of design models after repacking are indicated at bottom right. For reference, the energy of the HG4
641 crystal structure with bound transition state is -182.7 kcal/mol. In all cases, the transition state and transition state
642 analogue are show at the center of barrel. Side chains of all residues forming the binding pocket are shown with the exception
643 of Ala21 and Pro45, which were omitted for clarity. The sphere shows the alpha carbon of Gly83.
644